



PATENT

Case Docket No. WWF153.001APC

Date: August 5, 2002

RECEIVED
AUG 22 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Küpper, et al.
Appl. No. : 10/009,040
Filed : October 23, 2001
For : USE OF COXSACKIE
VIRUSES FOR IMPROVING
TRANSFECTION OF CELLS
Examiner : UNKNOWN
Group Art Unit : UNKNOWN

I hereby certify that this correspondence and all
marked attachments are being deposited with the
United States Postal Service as first class mail in an
envelope addressed to: Assistant Commissioner for
Patents, Washington, D.C. 20231, on

August 5, 2002
(Date)
Mark R. Benedict
Mark R. Benedict, Reg. No. 44,531

#8

TRANSMITTAL LETTER

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

ATTENTION: APPLICATION BRANCH

Dear Sir:

Enclosed for filing in the above-identified application are the following:

- (X) A Supplemental Information Disclosure Statement;
- (X) A PTO Form 1449 listing nine (9) references, copies of which are enclosed; and
- (X) A return prepaid postcard.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit
any overpayment, to Account No. 11-1410.

Mark R. Benedict
Mark R. Benedict
Registration No. 44,531
Attorney of Record

RECEIVED
AUG 20 2002
TECHNOLOGY CENTER 1700

WWELL53.001APC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Küpper, et al.)
App. No. : 10/009,040)
Mailed : October 23, 2001)
For : USE OF COXSACKIE)
VIRUSES FOR IMPROVING)
TRANSFECTION OF CELLS)
Examiner : UNKNOWN)

Group Art Unit UNKNOWN



SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Enclosed is form PTO-1449 listing nine (9) references that are also enclosed. This Supplemental Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 8/5/02

By: Mark R. Benedict

Mark R. Benedict
Registration No. 44,531
Attorney of Record
620 Newport Center Drive, Sixteenth Floor
Newport Beach, CA 92660
(949) 760-0404

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
WWELL53.001APCAPPLICATION NO.
10/009,040INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANTS
Küpper, et al.FILING DATE
October 23, 2001GROUP ART UNIT
UNKNOWNRECEIVED
AUG 22 2002
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

RECEIVED
AUG 20 2002
TECHNOLOGY CENTER 1700

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	Barr, et al., "Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus," Gene Therapy, Volume 1, pp. 51-58, (1994).
	Bowman, et al., "Bafilomycins: A class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells," Proceedings National Academy of Sciences, USA, Volume 85, pp. 7972-7976, dated November 1988.
	Drose, et al., "Inhibitory Effect of Modified Bafilomycins and Concanamycins on P- and V-Type Adenosinetriphosphatases," American Chemical Society, Biochemistry, Volume 32, pp. 3902-3906, (1993).
	Felgner, et al., "Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure," Proceeding National Academy of Sciences, USA, Volume 84, Biochemistry, pp. 7413-7417, dated November 1987.
	Kandolf, et al., "Molecular cloning of the genome of a cardiotropic Coxsackie B3 virus: Full-length reverse-transcribed recombinant cDNA generate infectious virus in mammalian cells," Proceedings National Academy of Sciences, USA, Volume 82, Medical Sciences, pp. 4818-4822, dated July 1985.
	Klump, et al., "Complete Nucleotide Sequence of Infectious Coxsackievirus B3 cDNA: Two Initial 5' Uridine Residues Are Regained during Plus-Strand RNA Synthesis," Journal of Virology, American Society for Microbiology, pp. 1573-1583, dated April 1990.
	Nabel, et al., "Recombinant Gene Expression in vivo Within Endothelial Cells of the Arterial Wall," Science, Volume 244, pp. 1342-1344, dated June 16, 1989.
	Nabel, et al., "Site-Specific Gene Expression in Vivo by Direct Gene Transfer into the Arterial Wall," Science Reports, Volume 249, pp. 1285-1288, dated September 14, 1990.
	Wagner, et al., "Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: Toward a synthetic virus-like gene-transfer vehicle," Proceedings National Academy of Sciences, USA, Volume 89, Biochemistry, pp. 7934-7938, September 1992.

H:\DOCS\CMS\CMS-2882.DOC\dns
080502

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	